[{"address1": "The Schr\u00f6dinger Building", "address2": "Oxford Science Park", "city": "Oxford", "zip": "OX4 4GE", "country": "United Kingdom", "phone": "44 18 6581 8941", "website": "https://www.exscientia.ai", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charit\u00e9 \u0096 Universit\u00e4tsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.", "fullTimeEmployees": 483, "companyOfficers": [{"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 54, "title": "Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 46, "title": "CFO, Chief Strategy Officer & Executive Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 545185, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Overington Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sara  Sherman", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Ireland", "title": "Executive VP of Legal & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Parker  Moss", "title": "Executive Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Rowland", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Law", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nikolaus  Krall", "title": "Executive Vice President of Precision Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.", "age": 59, "title": "Interim Chief Medical Officer & Clinical Development Lead", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.12, "open": 5.08, "dayLow": 5.05, "dayHigh": 5.265, "regularMarketPreviousClose": 5.12, "regularMarketOpen": 5.08, "regularMarketDayLow": 5.05, "regularMarketDayHigh": 5.265, "beta": 0.844, "forwardPE": -7.2394366, "volume": 260583, "regularMarketVolume": 260583, "averageVolume": 519651, "averageVolume10days": 602427, "averageDailyVolume10Day": 602427, "bid": 5.08, "ask": 5.15, "bidSize": 100, "askSize": 300, "marketCap": 649567488, "fiftyTwoWeekLow": 3.86, "fiftyTwoWeekHigh": 9.12, "priceToSalesTrailing12Months": 33.127678, "fiftyDayAverage": 5.2342, "twoHundredDayAverage": 5.639825, "currency": "USD", "enterpriseValue": 338689728, "floatShares": 92781968, "sharesOutstanding": 126375000, "sharesShort": 3747680, "sharesShortPriorMonth": 4482067, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0297, "heldPercentInsiders": 0.38499, "heldPercentInstitutions": 0.38654, "shortRatio": 7.04, "shortPercentOfFloat": 0.0615, "impliedSharesOutstanding": 126375000, "bookValue": 2.618, "priceToBook": 1.9633307, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -129327000, "trailingEps": -1.35, "forwardEps": -0.71, "pegRatio": -0.46, "enterpriseToRevenue": 17.273, "enterpriseToEbitda": -2.343, "52WeekChange": -0.32984293, "SandP52WeekChange": 0.2086575, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "EXAI", "underlyingSymbol": "EXAI", "shortName": "Exscientia Plc", "longName": "Exscientia plc", "firstTradeDateEpochUtc": 1633095000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "338b7c25-91d3-36d5-9c38-0f21999063b2", "messageBoardId": "finmb_408328234", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.14, "targetHighPrice": 10.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.33, "targetMedianPrice": 8.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 329911008, "totalCashPerShare": 2.612, "ebitda": -144574000, "totalDebt": 19449000, "quickRatio": 6.195, "currentRatio": 6.296, "totalRevenue": 19608000, "debtToEquity": 5.883, "revenuePerShare": 0.157, "returnOnAssets": -0.18330999, "returnOnEquity": -0.33233002, "freeCashflow": -89210872, "operatingCashflow": -105075000, "revenueGrowth": -0.082, "grossMargins": -0.34404, "operatingMargins": -5.2680497, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-07-20"}]